Showing results 1 to 6 of 6
Title | Author(s) | Issue Date | |
---|---|---|---|
Biomarker Signatures Correlate with Clinical Outcome in Refractory Metastatic Colorectal Cancer Patients Receiving Bevacizumab and Everolimus Journal:Molecular Cancer Therapeutics | 2015 | ||
2013 | |||
Direct Evidence of Target Inhibition with Anti-VEGF, EGFR, and mTOR Therapies in a Clinical Model of Wound Healing Journal:Clinical Cancer Research | 2015 | ||
Direct Evidence of Targeted Inhibition by Anti-angiogenic Agents from a Wound-healing Model in Patients with Advance Solid Tumors Proceeding/Conference:Targeting VEGF-mediated Tumor Angiogenesis in Cancer Therapy Conference | 2014 | ||
A leave-one-out cross-validation SAS macro for the identification of markers associated with survival Journal:Computers in Biology and Medicine | 2015 | ||
Use of plasma angiome to predict PFS in patients with metastatic colorectal cancer (mCRC) treated with capecitabine, oxaliplatin, and bevacizumab (XELOX-A) Proceeding/Conference:Journal of Clinical Oncology | 2010 |